---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-022334"
form_type: "8-K"
ticker: "CLNN"
cik: "0001822791"
company_name: "Clene Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:50:29.142545+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Clene reports Q3 net loss $11.0M; ALS survival benefit >90% and MS trial meet endpoints

## Summary
- Net loss of $11.0M ($0.17/share) vs net income $28.9M in Q3 2021; R&D $6.4M, G&A $3.6M.
- Cash & securities $16.2M at Sep 30; subsequent $10.8M equity raise and $5.0M loan commitment.
- ALS Healey trial: CNM-Au8 30 mg showed >90% reduction in risk of death at 24 weeks (p=0.028-0.075).
- VISIONARY-MS Phase 2 met primary LCLA endpoint (p=0.056) and secondary mMSFC (p=0.0207).
- Received EU Orphan Drug Designation for CNM-Au8 in ALS; ZnAg COVID trial topline Q4 2022.

## SEC filing metadata
- accession: 0000950170-22-022334
- form_type: 8-K
- ticker: CLNN
- cik: 0001822791
- company_name: Clene Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822791/000095017022022334/0000950170-22-022334-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822791/000095017022022334/clnn-20221107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-022334
- JSON: https://secwatch.observer/filing/0000950170-22-022334.json
- Plain text: https://secwatch.observer/filing/0000950170-22-022334.txt

## Key facts
- Earnings Releases
  Clene Inc. reported the quarter ended September 30, 2022 results: net income $11.0 million, EPS $0.17 per share.
  - Period: the quarter ended September 30, 2022
  - Net income: $11.0 million
  - EPS: $0.17 per share
  - Result: reported results
  source text: Clene reported a net loss of $11.0 million, or $0.17 per share, for the quarter ended September 30, 2022, compared to net income of $28.9 million, or $0.47 per basic share and $0.42 per diluted share, for the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822791/000095017022022334/0000950170-22-022334-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.